Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and ...
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...
Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update on January 7, 2026. With the appointment of Dr. Eileen ...
NDTV Profit on MSN
Anthropic’s Healthcare Push Explained: What Its New AI Features Mean For Doctors And Patients
Anthropic has unveiled new tools that enable both users and service providers to handle medical data, echoing steps already taken by OpenAI.
BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under ...
Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA ...
The battle for dominance in medical AI has escalated rapidly. Just days after OpenAI grabbed headlines with the debut of ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader in listeria-based cancer ...
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
Anthropic’s new offerings allow users and providers to work with medical data, mimicking similar moves by OpenAI.
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback